| Q67223712 | Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q94401199 | Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q37553969 | Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population. |
| Q35494498 | Association between self-perception period of lower urinary tract symptoms and International Prostate Symptom Score: a propensity score matching study |
| Q35527010 | Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. |
| Q53133756 | Association between the self-perception period of lower urinary tract symptoms and the International Prostate Symptom Score. |
| Q35860732 | Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement |
| Q34506218 | Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). |
| Q36737065 | Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management |
| Q89482897 | Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review |
| Q41769696 | Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events |
| Q80150264 | Complicated urinary tract infections |
| Q44846255 | Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia |
| Q94230282 | Convective radiofrequency water vapor thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q90649123 | Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q38058185 | Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system |
| Q40452225 | Does digital rectal examination predict prostate volume greater than 30 mL? |
| Q36590479 | Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia |
| Q35964540 | Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. |
| Q53088335 | Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial. |
| Q57223209 | Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study |
| Q46346409 | Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. |
| Q38463030 | Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms. |
| Q31144658 | Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50 |
| Q40783167 | Factors determining the amount of residual urine in men with bladder outlet obstruction: Could it be a predictor for bladder contractility? |
| Q26770425 | Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia |
| Q36845223 | Gland volume in the assessment of prostatic disease: does size matter? |
| Q35993964 | How should prostate specific antigen be interpreted? |
| Q39529499 | Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study |
| Q39827934 | Internal prostatic architecture on transrectal ultrasonography predicts future prostatic growth: Natural history of prostatic hyperplasia in a 15‐year longitudinal community‐based study |
| Q37118270 | Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists |
| Q37411445 | Involvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population. |
| Q41913071 | Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome |
| Q35816476 | Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. |
| Q38692706 | Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome |
| Q38253841 | Measurement of post-void residual urine |
| Q38098896 | Medical management of lower urinary tract symptoms in men with benign prostatic enlargement |
| Q37095232 | Medical management of lower urinary tract symptoms in men: current treatment and future approaches |
| Q37192948 | Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily |
| Q38388882 | Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients |
| Q55345009 | Metabolic syndrome and benign prostatic hyperplasia: An update. |
| Q45784694 | Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. |
| Q57280312 | Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia |
| Q39449659 | Non-neurogenic Chronic Urinary Retention: What Are We Treating? |
| Q39256832 | Outline of JUA clinical guidelines for benign prostatic hyperplasia |
| Q57492747 | Oxidative stress in the bladder of men with LUTS undergoing open prostatectomy: a pilot study |
| Q91818282 | Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms |
| Q95583611 | Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany |
| Q35894959 | Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the Prostate |
| Q41808660 | Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia |
| Q37895342 | Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone |
| Q47434739 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q33871847 | Sociodemographic Factors Related to Lower Urinary Tract Symptoms in Men: A Korean Community Health Survey |
| Q84160893 | Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study |
| Q53132058 | Survey on benign prostatic hyperplasia distribution and treatment patterns for men with lower urinary tract symptoms visiting urologists at general hospitals in Korea: a prospective, noncontrolled, observational cohort study. |
| Q38805656 | Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence? |
| Q38736795 | Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume |
| Q37531050 | Testosterone replacement therapy and voiding dysfunction |
| Q57582241 | The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia |
| Q55331840 | The association of benign prostatic hyperplasia with lower urinary tract stones in adult men: A retrospective multicenter study. |
| Q38111255 | The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis |
| Q37167114 | The effect of Bongardia Chrysogonum on prostate tissue in a rat model of STZ-induced diabetes |
| Q33807378 | The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment |
| Q36898650 | The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study |
| Q38136528 | The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP. |
| Q52741568 | The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. |
| Q89005504 | The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH) |
| Q55019942 | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. |
| Q37323301 | The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia |
| Q44643100 | The value of respective urodynamic parameters for evaluating the occurrence of complications linked to benign prostatic enlargement |
| Q37323306 | Voiding dysfunction in men: pathophysiology and risk factors |
| Q86590305 | [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia] |